Mar 23, 2004

Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials

Abdus S Wahed, A A Tsiatis


Two-stage designs, where patients are initially randomized to an induction therapy and then depending upon their response and consent, are randomized to a maintenance therapy, are common in cancer and other clinical trials. The goal is to compare different combinations of primary and maintenance therapies to find the combination that is most beneficial. In practice, the analysis is usually conducted in two separate stages which does not directly address the major objective of finding the best combination. Recently Lunceford, Davidian, and Tsiatis (2002, Biometrics58, 48-57) introduced ad hoc estimators for the survival distribution and mean restricted survival time under different treatment policies. These estimators are consistent but not efficient, and do not include information from auxiliary covariates. In this article we derive estimators that are easy to compute and are more efficient than previous estimators. We also show how to improve efficiency further by taking into account additional information from auxiliary variables. Large sample properties of these estimators are derived and comparisons with other estimators are made using simulation. We apply our estimators to a leukemia clinical trial data set that motivated ...Continue Reading

Mentioned in this Paper

Antineoplastic Agents
Log-Linear Models
Granulocyte-Macrophage Colony-Stimulating Factor
Proteins, Recombinant DNA
Survival Analysis
Chaos Theory
Two-Parameter Models
Acute Myeloid Leukemia, M1

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.